ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, is pleased to announce that Suresh Vazirani, Chairman of ERBA Diagnostics, will be a key note speaker at the International Marketing Brief (IMB) in conjunction with the AACC. Over 800 of the owners and senior officers of worldwide diagnostic companies and distributors are expected to attend the event. ERBA Diagnostics Inc., USA will be exhibiting the full range of products from ERBA international group of companies in USA, Italy, Czech Republic, India and Turkey, including not only the Autoimmune and Infectious Elisa product lines, but also the full line of biochemistry, clinical chemistry and urine analysis products. About 10,000 potential customers are expected to visit the Expo from all regions of the world. ERBA will also be exhibiting for the first time in USA its new prototype of its state-of-the-art microtiter and IFA processor LISA XL. Most recently, IVAX Diagnostics, Inc. (NYSE MKT: IVD) has become ERBA Diagnostics (NYSE MKT: ERB). With this corporate name and ticker symbol change, ERBA Diagnostics signals its serious intention to develop brand recognition and collaboration through the worldwide network of companies affiliated with its majority stockholder – ERBA Diagnostics Mannheim GmbH. About ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. ( www.erbadiagnostics.com), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.L. (Europe) and ImmunoVision, Inc. (U.S.). Safe Harbor Statement Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by these forward-looking statements. These forward-looking statements are based largely on ERBA Diagnostics’ expectations, beliefs and assumptions and on the information currently available it and are subject to a number of risks and uncertainties, including, but not limited to: the risks and uncertainties related to ERBA Diagnostics’ financial condition, results of operations and cash flows; the risks and uncertainties relating to ERBA Diagnostics’ technological, strategic and business initiatives, including, without limitation, that its new instrumentation system development may not produce, and the prototype may not result in, a commercially viable product at the cost anticipated or in the time frame anticipated, or at all; the risks and uncertainties relating to ERBA Diagnostics’ relationships with ERBA Diagnostics Mannheim GmbH, including, without limitation, that ERBA Diagnostics may not be able to successfully develop brand recognition and collaboration through the worldwide network of ERBA companies, that ERBA Diagnostics Mannheim GmbH has voting control of ERBA Diagnostics’ common stock, and that conflicts of interest exist with ERBA Diagnostics Mannheim GmbH and with ERBA Diagnostics’ officers, employees and other directors, including, without limitation, directors that are also executive officers of ERBA Diagnostics Mannheim GmbH; the risk and uncertainties related to that ERBA Diagnostics may not achieve growth through value and service; and other economic, competitive, governmental, technological and other risks and factors that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risks and uncertainties set forth above, you should consider the economic, competitive, governmental, technological and other risks and factors discussed elsewhere in ERBA Diagnostics’ periodic filings with the Securities and Exchange Commission, including, without limitation, in the section entitled, Risk Factors’ in such filings. Many of these risks, uncertainties and factors are beyond ERBA Diagnostics’ control.